Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Safety and Biomarker Study of PTC-589 in Participants With Parkinson's Disease
Details : PTC-589 is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 04, 2015
Lead Product(s) : Vatiquinone
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Optic Atrophy, Hereditary, Leber.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 25, 2014
Lead Product(s) : Vatiquinone
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vatiquinone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Protective Effects of EPI-743 on Noise-Induced Hearing Loss
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hearing Loss, Noise-Induced.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 07, 2014
Lead Product(s) : Vatiquinone
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vatiquinone
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Autism Spectrum Disorder.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 27, 2014
Lead Product(s) : Vatiquinone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vatiquinone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of EPI-743 in Children With Pearson Syndrome
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of VLCAD Deficiency.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 04, 2014
Lead Product(s) : Vatiquinone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vatiquinone
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : University of South Florida
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2A Trial of EPI-743 for Patients With Parkinson's Disease
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Parkinson Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2013
Lead Product(s) : Vatiquinone
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : University of South Florida
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vatiquinone
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phase 2 Study of EPI-743 for Treatment of Rett Syndrome
Details : EPI-743 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rett Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 02, 2013
Lead Product(s) : Vatiquinone
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
